Total Funding
38
Total FundingPost-IPO Debt raised
Growth Score
pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
133704
CTI BioPharma is a biopharmaceutical company developing oncology products for the treatment of blood-related cancers.
Acquired by 
Swedish Orphan Biovitrum
David Kirske: EVP, Chief Financial Officer
Nancy L. Boman: SVP, Clinical Development and Regulatory AffairsPast Role: Genentech, Associate Director
About the Company
CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic
agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.
